Social Disparities in Lung Cancer Risk and Screening

2022 ◽  
Vol 32 (1) ◽  
pp. 23-31
Author(s):  
Vignesh Raman ◽  
Valeda Yong ◽  
Cherie P. Erkmen ◽  
Betty C. Tong
2019 ◽  
Author(s):  
A Tufman ◽  
S Schneiderbauer ◽  
D Kauffmann-Guerrero ◽  
F Manapov ◽  
C Schneider ◽  
...  

2013 ◽  
Vol 12 (6) ◽  
pp. 1281-1285 ◽  
Author(s):  
Tiberius Dicu ◽  
Doina Todea ◽  
Constantin Cosma ◽  
Loredana Rosca ◽  
Alexandra Cucos Dinu ◽  
...  

2018 ◽  
Vol 238 (5) ◽  
pp. 395-421 ◽  
Author(s):  
Nicolas R. Ziebarth

Abstract This paper empirically investigates biased beliefs about the risks of smoking. First, it confirms the established tendency of people to overestimate the lifetime risk of a smoker to contract lung cancer. In this paper’s survey, almost half of all respondents overestimate this risk. However, 80% underestimate lung cancer deadliness. In reality, less than one in five patients survive five years after a lung cancer diagnosis. Due to the broad underestimation of the lung cancer deadliness, the lifetime risk of a smoker to die of lung cancer is underestimated by almost half of all respondents. Smokers who do not plan to quit are significantly more likely to underestimate this overall mortality risk.


Epigenetics ◽  
2021 ◽  
pp. 1-16
Author(s):  
Marina Laplana ◽  
Matthias Bieg ◽  
Christian Faltus ◽  
Svitlana Melnik ◽  
Olga Bogatyrova ◽  
...  

BMC Cancer ◽  
2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Hui Zeng ◽  
Zhuoyu Yang ◽  
Jiang Li ◽  
Yan Wen ◽  
Zheng Wu ◽  
...  

Abstract Background Published findings suggest sex differences in lung cancer risk and a potential role for sex steroid hormones. Our aim was to perform a meta-analysis to investigate the effects of sex steroid hormone exposure specifically on the risk of lung cancer in women. Methods The PubMed, MEDLINE, Web of Science, and EMBASE databases were searched. The pooled odds ratios (ORs) and 95% confidence intervals (95% CIs) for female lung cancer risk associated with sex steroid hormones were calculated overall and by study design, publication year, population, and smoking status. Sensitivity analysis, publication bias, and subgroup analysis were performed. Results Forty-eight studies published between 1987 and 2019 were included in the study with a total of 31,592 female lung cancer cases and 1,416,320 subjects without lung cancer. Overall, higher levels of sex steroid hormones, both endogenous (OR: 0.92, 95% CI: 0.87–0.98) and exogenous (OR: 0.86, 95% CI: 0.80–0.93), significantly decreased the risk of female lung cancer by 10% (OR: 0.90, 95% CI: 0.86–0.95). The risk of lung cancer decreased more significantly with a higher level of sex steroid hormones in non-smoking women (OR: 0.88, 95% CI: 0.78–0.99) than in smoking women (OR: 0.98, 95% CI: 0.77–1.03), especially in Asia women (OR: 0.84, 95% CI: 0.74–0.96). Conclusions Our meta-analysis reveals an association between higher levels of sex steroid hormone exposure and the decreased risk of female lung cancer. Surveillance of sex steroid hormones might be used for identifying populations at high risk for lung cancer, especially among non-smoking women.


Cancers ◽  
2021 ◽  
Vol 13 (8) ◽  
pp. 1982
Author(s):  
In Young Cho ◽  
Kyungdo Han ◽  
Dong Wook Shin ◽  
Mi Hee Cho ◽  
Jung Eun Yoo ◽  
...  

We investigated whether visit-to-visit variability in metabolic parameters is associated with lung cancer risk. We used nationally representative data from the Korean National Health Insurance System, and 8,011,209 lung-cancer-free subjects who underwent over three health examinations from 2005 to 2010 were followed until 2017. Variability of fasting blood glucose, total cholesterol, systolic blood pressure, and body weight were measured by the variability independent of the mean, assessed by quartiles. There were 44,982 lung cancer events. The hazard ratio (HR) and 95% confidence interval (CI) for lung cancer risk was 1.07 (1.04, 1.10) for fasting blood glucose in the highest quartile, 1.08 (1.05, 1.10) for systolic blood pressure, 1.04 (1.01, 1.07) for weight, and 1.11 (1.08, 1.14) for total cholesterol. When comparing ≥3 vs. 0 high-variability metabolic parameters, the HR for lung cancer was 1.18 (95% CI, 1.14, 1.22). However, while ≥3 high-variability parameters showed an increased lung cancer risk in men (HR 1.26, 95% CI 1.21, 1.31), women did not show increased risk (HR 0.99, 95% CI 0.92, 1.06). High variability in each metabolic parameter, and a higher number of high-variability parameters, were associated with increased lung cancer risk.


Sign in / Sign up

Export Citation Format

Share Document